compound memphi hope
amerisourcebergen solid result came face headwind around memphi
pharmedium facil manag believ come back phase
fulli oper better perform driven expans
anchor client specialti independ custom base view
remain well posit benefit share gain walgreen relat
acquir store well improv purchas
develop wbad joint ventur continu grow believ continu
gener consist free cash flow gener even intermedi
pharmedium headwind potenti supplement core growth
redeploy capit note risk busi relat market-wid
gener profit well on-going pharmedium headwind believ
price current valuat all-in see attract upsid potenti current
valuat thu reiter buy rate
reduc ep opex/pharmedium overhang
reduc ep ep
reduc ebit outlook due primarili continu
pharmedium headwind well increas interest expens although
somewhat off-set slightli lower tax rate maintain price
object equat ep estim
upcom event catalyst
guid alreadi way compani specif news may
limit near-term macro level variou price data point manufactur
comment iqvia data influenc group sentiment final two thing
watch dc front first to-be-reschedul press confer drug
price presid trump/hh secretari hous opioid hear
may like garner widespread attent well given import topic
appear three major distributor ceo separ anoth catalyst
iqvia mid-month prescript updat may
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
one largest drug distributor us
sizabl global gener sourc joint ventur
partnership
anim health unit oper
companion product anim distribut
transport logist technolog
compani base chesterbrook pa
buy rate driven long-term cash flow
gener stori trade larger-than-
expect discount rel histor averag
although premium relat potenti
deal appear remov share
think steadi revenu gener
provid solid core ebit growth even
headwind pricing/volum given
histor activ expect compani
like continu deploy toward
note earn call
total revenu ahead street estim
pharmaceut segment revenu ahead estim
aid contribut smith also impact
adjust ep well ahead street
driven better gross margin opex manag
includ headwind consolid brazil
stabl competit market
brand inflat track in-lin expect
commit improv qualiti program
compani close oper decemb
expect bring memphi back on-line fiscal year phase
manag wont fulli on-line fiscal
dont access patient inform allow
interfer clinic decis
compens associ base opioid sale
success grow gener volum
addit equiti invest profarma specialti joint ventur
requir consolid entiti
profarma pharmaceut distribut
brazil specialti report
oper increas brazil contribut one-third dollar increas
exclud brazil hd smith oper expens in-lin
oper margin primarili due lower pharmaceut
revenu benefit anchor custom emphasi
revenu driver complet hd smith growth includ
servic half pharmaci quarter
specialti distribut oncolog physician distribut specialti
revenu hepat
anim health revenu growth high-singl digit
brazil expect immateri impact oper incom
timelin take longer expect
revis assum memphi facil phase
contribut fiscal memphi facil nomin
slightli faster ramp busi
oper expens increas determin remedi
cost direct cost oper expens
chang net neutral repres chang oper
opex growth in-lin begin year expect
expect flat oper incom growth year
updat assumpt around brand inflat rate gener
chang oper profit flat full year
exclud remedi cost anyth would caus
chang much chang expect relat
took ebit guidanc
relat distribut
pharmedium volum go remedi
site
custom go back in-hous that compani
feel pharmedium oper get
contract negoti specialti brand drug
made lot progress
thought anim health spin
convinc anim health great addit abc
think propos tabl address drug
price could mean
appear self-regul brand
big invest complex implement
implement largest custom went well
pharmedium remedi cost
abc adjust result one-tim non-
march ytd adjust
full year remedi cost adjust
price object base ep multipl
five-year averag five-year high although would argu
artifici high due period gener inflat also repres
similar discount vs last five year think discount
warrant given incorpor modest growth slowdown seen rest
suppli chain well encompass competit risk
downsid risk po increment wors drug price pressur increas
competit creat gross profit headwind risk amazon anoth disrupt
forc enter suppli chain market lack avail attract capit deploy
opportun fluctuat relat press report hypothet
acquisit upsid risk potenti volum pickup increas
buyside/sellsid spread opportun cost save
michael cherni herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
